4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kontafarma China Holdings Limited (1312) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Wan Chai, Hong Kong with about 636 employees. Its market capitalization is roughly HKD 162 million. In the fiscal year ended 2025-12-31, 1312 reported HKD 915M in revenue and (HKD 428M) in net income.
Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediates in Mainland China, Singapore, Taiwan, and internationally. The company operates through Pharmaceutical Business and Fitness Business segments.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | HKD 915M | HKD 898M | HKD 809M | HKD 894M | — |
| Gross Profit | HKD 514M | HKD 516M | HKD 471M | HKD 506M | — |
| Operating Income (EBIT) | (HKD 232M) | (HKD 47M) | (HKD 136M) | (HKD 97M) | — |
| Net Income | (HKD 428M) | (HKD 76M) | (HKD 29M) | (HKD 42M) | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | HKD 1.1B | HKD 1.6B | HKD 1.7B | HKD 2.1B | — |
| Total Liabilities | HKD 589M | HKD 626M | HKD 665M | HKD 964M | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1312 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms